Plasma exchange for Guillain-Barre syndrome

Hôpital Raymond Poincaré, Garches, France.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 01/2012; 7(7):CD001798. DOI: 10.1002/14651858.CD001798.pub2
Source: PubMed

ABSTRACT Guillain-Barré syndrome is an acute paralysing disease caused by peripheral nerve inflammation. This is an update of a review first published in 2001 and last updated in 2008.
To assess the effects of plasma exchange for treating Guillain-Barré syndrome.
We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 June 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (January 1966 to June 2011) and EMBASE (January 1980 to June 2011).
Randomised and quasi-randomised trials of plasma exchange versus sham exchange or supportive treatment.
Two review authors agreed the selection of eligible studies and independently assessed the risk of bias in included studies. Data were extracted by one review author and checked by a second review author. Likewise data for adverse events were extracted by one review author and checked by a second review author.
In the first version of this review there were six eligible trials concerning 649 participants comparing plasma exchange with supportive treatment. No new eligible trials have been identified in subsequent updates. Overall the included trials had a low risk of bias.Primary outcomes In one trial with 220 severely affected participants, the median time to recover walking with aid was significantly faster; with plasma exchange (30 days) than without (44 days). In another trial with 91 mildly affected participants, the median time to onset of motor recovery was significantly shorter with plasma exchange (six days) than without (10 days). After four weeks, combined data from three trials accounting for a total of 349 patients showed that plasma exchanged significantly increased the proportion of patients who recovered the ability to walk with assistance (risk ratio (RR) 1.60, 95% confidence interval (CI) 1.19 to 2.15).Secondary outcomes In five trials with 623 participants in total, the RR of being improved by one or more grades after four weeks was 1.64 (95% CI 1.37 to 1.96) in favour of plasma exchange. Participants treated with plasma exchange also fared significantly better in time to recover walking without aid (three trials with 349 participants, RR 1.72 (95% CI 1.06 to 2.79)) and requirement for artificial ventilation (five trials with 623 participants, RR 0.53 (95% CI 0.39 to 0.74)). There were significantly more participants with relapses by the end of follow-up in the plasma exchange than the control group (6 trials with 649 participants, RR 2.89 (95% CI 1.05 to 7.93)). Despite this, at one year the likelihood of full muscle strength recovery was significantly greater with plasma exchange than without (five trials with 404 participants, RR 1.24 (95% CI 1.07 to 1.45)) and the likelihood of severe motor sequelae was significantly less (six trials with 649 patients, RR 0.65 (95% CI 0.44 to 0.96)). There was no significant difference in deaths (six trials with 649 participants, RR 0.86 (95% CI 0.45 to 1.65)) or participants with adverse events (three trials with 556 participants), except fewer arrhythmias in plasma exchange treated participants (RR 0.75 (95% CI 0.56 to 1.00)).
Moderate-quality evidence shows significantly more improvement with plasma exchange than supportive care alone in adults with Guillain-Barré syndrome without a significant increase in serious adverse events. There was a small but significant increase in the risk of relapse during the first six to 12 months after onset in people treated with plasma exchange compared with those that were not treated. Despite this, after one year, full recovery was significantly more likely and severe residual weakness less likely with plasma exchange.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMEN Existen varios padecimientos del sistema nervioso periférico inmunomediados que abarcan alteraciones musculares, de los nervios y la unión entre ambos. Dado el origen inmunológico de dichos padecimientos, el tratamiento se basa en la inmunosupresión y/o la inmunomoduilación. La aplicación de inmunoglobulina intravenosa y el recambio plasmático se consideran dentro del tratamiento de dichas enfermedades como terapias inmunomoduladoras que retrasan la progresión y mejoran la calidad de vida de quienes padecen estos problemas. La presente revisión se enfoca en las indicaciones de la inmunoglobulina intravenosa y el recambio plasmático en padecimientos del sistema nervioso periférico. Palabras clave: recambio plasmático, inmunoglobulina intravenosa, plasmaféresis, sistema nervioso periférico. Treatment of neuromuscular disorders with immunoglobulin and plasmapheresis ABSTRACT There are several immunomediated diseases of the peripheral nervous system, such as muscular, nervous and neuromuscular junction abnormalities. Thinking about de immunological basis of those illnesses, the treatment is immunomodulated and immunoregulated-based. Both intravenous immunoglobulin and plasma exchange are considerate as immunomodulatory therapies which delay the progression and improve the patients' quality of life. This review focuses in the indications of these treatments en peripheral nervous system diseases.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Intravenous IgG (IVIg) contains polyclonal immunoglobulin G (IgG) from thousands of donors. It is administered at a low dose at regular intervals as antibody replacement therapy and at a higher dose as immunomodulatory treatment in various auto-immune or auto-inflammatory diseases. The working mechanism of immunomodulation is not well understood. Many different explanations have been given. During the last decade, we have focused on classical antibody binding via the Fc-domain of the IgG molecules to the common IgG receptors, i.e. the Fcγ receptors (FcγRs). Variation in the genes encoding human FcγRs determines function as well as expression among immune cells. As described here, NK cells and myeloid cells, including macrophages, can express different FcγR variants, depending on the individual's genotype, copy number variation (CNV), and promoter polymorphisms. B-cells seem to only express the single inhibitory receptor. Although these inhibitory FcγRIIb receptors are also expressed by monocytes, macrophages, and only rarely by NK cells or neutrophils, their presence is unlikely to explain the immunomodulatory capacity of IVIg, nor does the sialylation of IgG. Direct IVIg effects at the level of the activating FcγRs, including the more recently described FcγRIIc, deserve renewed attention to describe IVIg-related immunomodulation.
    Frontiers in Immunology 01/2014; 5:674. DOI:10.3389/fimmu.2014.00674
  • Asian Journal of Transfusion Science 01/2015; 9(1):106. DOI:10.4103/0973-6247.150974


Available from